These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9360543)

  • 21. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.
    Swerdloff RS; Wang C
    Aging Male; 2003 Sep; 6(3):207-11. PubMed ID: 14628501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
    Raynaud JP; Legros JJ; Rollet J; Augès M; Bunouf P; Sournac M; Fiet J
    J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):168-76. PubMed ID: 18325757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study.
    Morley JE; Perry HM; Kaiser FE; Kraenzle D; Jensen J; Houston K; Mattammal M; Perry HM
    J Am Geriatr Soc; 1993 Feb; 41(2):149-52. PubMed ID: 8426037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels.
    Leder BZ; Rohrer JL; Rubin SD; Gallo J; Longcope C
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1174-80. PubMed ID: 15001605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short term testosterone replacement therapy improves libido and body composition.
    Andrade ES; Clapauch R; Buksman S
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):996-1004. PubMed ID: 20126853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
    J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.
    Zgliczynski S; Ossowski M; Slowinska-Srzednicka J; Brzezinska A; Zgliczynski W; Soszynski P; Chotkowska E; Srzednicki M; Sadowski Z
    Atherosclerosis; 1996 Mar; 121(1):35-43. PubMed ID: 8678922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testosterone supplementation does not worsen lower urinary tract symptoms.
    Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
    J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal testosterone therapy in the treatment of male hypogonadism.
    Ahmed SR; Boucher AE; Manni A; Santen RJ; Bartholomew M; Demers LM
    J Clin Endocrinol Metab; 1988 Mar; 66(3):546-51. PubMed ID: 3350906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
    Rhoden EL; Morgentaler A
    J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men.
    Yaron M; Greenman Y; Rosenfeld JB; Izkhakov E; Limor R; Osher E; Shenkerman G; Tordjman K; Stern N
    Eur J Endocrinol; 2009 May; 160(5):839-46. PubMed ID: 19174534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.